机构：中金公司 研究员：冯喜鹏/赵丽萍/张琎/肖楷 盈利预测与估值 我们预计公司25~26 年non-IFRS EBIT 分别为1.83 亿元、2.32 亿元，CAGR为34%。考虑到公司利润稳 定产出，且在手现金亦有望贡献业务角度价值，我们综合行业水平给予2025 年40x 的EV/EBIT 估值， 并单独考虑现金价值，得到目标价17.5 港币（14%上行空间），给予跑赢行业评级。 风险 投资亮点 药企对线上医疗营销投入意愿可能波动；竞争加剧致订单降价风险；医师用户流失风险；新业务发展不 及预期风险；流动性风险；行业政策波动风险；与 M3 合作不畅及利益冲突风险。 首次覆盖医脉通（02192）给予跑赢行业评级，目标价17.50 港元，基于相对估值法，对应估值倍数40x 的2025 年EV/EBIT，公司是第三方数字医师平台行业翘楚。理由如下： 医疗产业营销端迎来升级，第三方医师平台有望脱颖而出。传统医药营销活动多以线下方式为主，疫情 扰动、医疗行业集中整顿等因素令药企对线上医疗营销业态关注度提升。根据弗若斯特沙利文数据及我 们测算，2023 年泛数字医疗营销投入占药企营销投入比重约9%（vs 2018年不足 ...

Group 1 - The core viewpoint of the report is that the third-party digital physician platform industry is expected to thrive, with the company being a leader in this sector, supported by stable profit generation and cash reserves [1][2] - The report projects that the company's non-IFRS EBIT will reach 183 million yuan and 232 million yuan in 2025 and 2026 respectively, with a CAGR of 34% [1] - The digital marketing investment in the healthcare industry is expected to grow significantly, with the proportion of digital marketing in pharmaceutical marketing rising from less than 1% in 2018 to approximately 9% in 2023, and the market size potentially exceeding 10 billion yuan by 2030 [2] Group 2 - The company has developed a strong brand identity through its professional clinical and research software applications, achieving a registered physician user base of over 4 million by 2024, which represents an 88% penetration rate among practicing physicians in China [3] - The company is expanding its digital medical marketing services to pharmaceutical clients, with a projected CAGR of 33% in the number of cooperative products with pharmaceutical companies from 2022 to 2024 [3] - The company is well-positioned to balance the needs of its physician user base with commercial opportunities, creating a strong competitive barrier through user loyalty and value creation [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 醫脈通科技有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | 本月底法定 ...

Investment Rating - The report indicates a positive investment outlook for the AI healthcare industry, highlighting significant growth potential and increasing investment activity in the sector [3][10][46]. Core Insights - The AI healthcare sector is entering a new phase characterized by multi-modal integration and practical applications, driven by advancements in large models and generative AI [3][7]. - Clinical decision support and drug development are leading the commercialization efforts, while health management remains an area with untapped potential [3][14]. - The report emphasizes the importance of third-party vendors in reducing model hallucination rates and enhancing the reliability of AI applications in healthcare [3][18][21]. Summary by Sections AI Healthcare Trends - The industry is experiencing heightened investment interest and technological advancements, with major players accelerating their presence in the AI healthcare space [9][10][13]. - The integration of AI into clinical workflows is becoming standard, with AI-assisted diagnosis systems deployed in 89% of tertiary hospitals [8][14]. AI Healthcare Application Penetration - AI applications are diversifying across clinical diagnosis, drug development, health management, and AI for science (AI4S), with varying levels of maturity and market potential [30][31]. - The report identifies key areas of application, including intelligent clinical decision support, drug discovery, and personalized health management [36][39]. Key Companies in AI Clinical Diagnosis - Companies like Tempus AI and 嘉和美康 are leading in AI-assisted clinical diagnosis, focusing on electronic medical records and data-driven healthcare solutions [47][51]. - The report highlights the importance of data barriers and scenario positioning in determining the value of AI diagnostic tools [3][46]. Key Companies in AI Health Management - Companies such as 阿里健康 and 京东健康 are leveraging AI to enhance online healthcare services, with a focus on chronic disease management and personalized health plans [39][44]. - The report notes that the integration of insurance and healthcare services is crucial for the growth of AI health management solutions [39][44]. Key Companies in AI Drug Development - The report discusses the role of AI in accelerating drug development processes, with companies like Recursion and 晶泰控股 focusing on preclinical research and drug discovery [38][44]. - AI is expected to significantly reduce the time and cost associated with traditional drug development methods [38][44]. AI4S and Broader Applications - AI4S is identified as a growing field with applications in various scientific domains, including life sciences and materials science, although it faces longer conversion cycles [42][44]. - The report emphasizes the need for innovative approaches to data generation and modeling in AI4S applications [42][44].

Core Viewpoint - The Hong Kong internet sector is experiencing a competitive landscape, highlighted by a significant promotional battle between Alibaba's Ele.me and Meituan, indicating aggressive market share acquisition strategies [3][4]. Group 1: Market Performance - As of July 7, 2025, the CSI Hong Kong Internet Index (931637) decreased by 0.46%, with mixed performance among constituent stocks [3]. - Notable gainers included Zhong An Online (06060) up 5.52%, Ping An Good Doctor (01833) up 3.23%, and Dongfang Zhenxuan (01797) up 3.11% [3]. - Conversely, Kingdee International (00268) led the declines at 4.29%, followed by Kingsoft (03888) down 4.06% and Yimaitong (02192) down 2.92% [3]. - The Hong Kong Internet ETF (159568) saw a slight increase of 0.06%, closing at 1.67 yuan, with a 1.21% rise over the past two weeks [3]. Group 2: Liquidity and Trading Activity - The Hong Kong Internet ETF recorded a turnover of 20.01% during the trading session, with a transaction volume of 63.6452 million yuan, indicating active market participation [3]. - Over the past year, the ETF has averaged daily trading volume of 174 million yuan [3]. Group 3: Industry Trends and Investment Outlook - According to CICC, the internet sector has entered a new investment cycle since 2025, with AI, overseas expansion, and instant retail emerging as key focus areas [4]. - The Hong Kong Internet ETF has shown a net value increase of 47.93% over the past year, ranking 218 out of 2897 index funds, placing it in the top 7.53% [4]. - The ETF's highest monthly return since inception was 30.31%, with a historical one-year holding profitability rate of 100% [4]. Group 4: Valuation and Tracking Accuracy - The latest price-to-earnings ratio (PE-TTM) for the CSI Hong Kong Internet Index is 21.75, indicating a valuation below 89.06% of the past year, suggesting historical low valuation levels [5]. - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.052% over the past three months [5]. - The top ten weighted stocks in the index account for 72.11% of the total, including major players like Xiaomi Group-W (01810), Tencent Holdings (00700), and Alibaba-W (09988) [5].

Core Insights - The company has established itself as a leading platform in the medical digital marketing industry, leveraging 29 years of data asset accumulation to create a unique AI + healthcare platform [1] - The digital precision marketing market in China has surpassed 3 billion RMB in 2023, with a CAGR of 33.5% from 2019 to 2023, indicating significant growth potential [2] - The company has developed a mature profit model in digital marketing solutions, achieving a revenue increase from 80 million RMB in 2018 to 510 million RMB in 2024, with a CAGR of 36.8% [3] - The introduction of AI-driven products, such as the MedSeeker medical model, is expected to enhance customer acquisition capabilities and accelerate the commercialization of content [4] Company Overview - The company has over 7 million registered users and 2.65 million monthly active users, providing a robust foundation for value-added services to pharmaceutical and medical device companies [1] - As of 2024, the company has partnered with 228 clients and 506 products, showcasing its strong market presence [3] - The company’s revenue from precision marketing and enterprise solutions has shown consistent growth, reflecting its effective business strategy [3] Industry Trends - Digital precision marketing is becoming a preferred choice for pharmaceutical companies, especially in the context of increased regulatory scrutiny and the need for compliance [2] - The market for digital marketing in healthcare is evolving, with platforms now rivaling traditional channels in terms of reach and influence [2] - The integration of AI technologies in healthcare is set to transform the industry, with the company positioned to capitalize on this trend through its innovative products [4]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4][7]. Core Insights - The company is a leader in the medical digital marketing sector, leveraging 29 years of data assets to create a unique AI+medical platform. It has over 7 million registered users, with 2.65 million monthly active users, providing a strong foundation for value-added services to pharmaceutical companies and patients [1][12]. - The digital marketing landscape is rapidly expanding, with the market size exceeding 3 billion RMB in 2023 and a CAGR of 33.5% from 2019 to 2023. The shift towards digital marketing is driven by the need for compliance and efficiency in the medical field [2][58]. - The company has successfully monetized its large physician user base, achieving a compound annual growth rate (CAGR) of 36.8% in revenue from precision marketing and enterprise solutions from 2018 to 2024 [3][26]. Summary by Sections 1. Company Overview - The company has established itself as a leading medical information service platform, with a focus on enhancing user experience through a diverse range of products. It has developed AI products like MedAssister and MedSeeker, supported by a vast database of medical literature [1][12]. - The user base includes over 4 million registered physicians, achieving an 88% coverage rate among practicing physicians in China [12][68]. 2. Digital Marketing Industry - The digital marketing sector is witnessing significant growth, with a market size of 3 billion RMB in 2023. The industry is characterized by a shift towards compliance and efficiency, making digital marketing a preferred choice for pharmaceutical companies [2][58]. - The company’s digital marketing solutions have shown a clear advantage over traditional methods, offering better compliance, cost-effectiveness, and time efficiency [2][45]. 3. AI Empowerment - The company is leveraging AI to enhance the effectiveness of its data assets, launching products that integrate extensive medical data to improve customer acquisition and content generation [4][66]. - The forecasted net profits for 2025, 2026, and 2027 are projected to be 322 million, 364 million, and 415 million RMB, respectively, with corresponding growth rates of 2.2%, 13.2%, and 13.8% [4][6]. 4. Financial Forecast and Valuation - The company’s revenue is expected to grow from 558 million RMB in 2024 to 1.092 billion RMB in 2027, with a CAGR of 35.5% from 2024 to 2027 [6][26]. - The projected P/E ratios for 2025, 2026, and 2027 are 26, 23, and 20, respectively, indicating a favorable valuation outlook [4][6].

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Sector shows a recent upward trend, indicating potential growth in the healthcare sector within the Hong Kong market [1][2]. Group 1: Index Performance - The China Securities Hong Kong Stock Connect Medical Comprehensive Index is currently at 1476.05 points, having increased by 3.68% over the past month, 0.03% over the past three months, and 14.44% year-to-date [1]. - The index is based on a sample of securities classified according to the China Securities Industry Classification Standard, reflecting the overall performance of different industry securities within the Hong Kong Stock Connect [1]. Group 2: Index Holdings - The top ten weighted stocks in the index include JD Health (17.13%), Alibaba Health (14.04%), Sinopharm (11.67%), Weigao Group (7.18%), MicroPort Medical (5.1%), Ping An Good Doctor (4.32%), Shanghai Pharmaceuticals (3.91%), Xianjian Technology (3.56%), Yimaitong (2.93%), and MicroPort Robotics-B (2.88%) [1]. - The index is exclusively composed of stocks listed on the Hong Kong Stock Exchange, with a total market share of 100% [1]. Group 3: Industry Composition - The industry composition of the index shows that pharmaceutical commerce accounts for 49.25%, medical consumables for 23.73%, medical services for 22.88%, medical devices for 3.24%, and in vitro diagnostics for 0.90% [2]. - The index sample is adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2].

截至2025年5月13日 09:39，恒生医疗保健指数(HSHCI)强势上涨1.38%，成分股百济神州(06160)上涨5.16%，医脉通(02192)上涨5.15%，乐普生物-B(02157)上 涨4.67%，信达生物(01801)，翰森制药(03692)等个股跟涨。恒生医疗ETF(513060)上涨1.72%，最新价报0.47元。流动性方面，恒生医疗ETF盘中换手 3.08%，成交3.05亿元。拉长时间看，截至5月12日，恒生医疗ETF近1月日均成交13.50亿元，排名可比基金第一。 德邦证券指出，AI的发展带动AI医疗的全面普及，大量医疗企业接入DS、华为等AI模型，开始摸索AI在医疗的应用。我们认为，1）拥有大量底层病人数据 的企业将有很大应用落地空间，2）拥有医保数据的企业有望深入应用AI，3）AI制药继续升级，建议关注此类公司。此外，积极关注1）创新药及其产业链 的技术革新与BD潜力；2）有业绩，基本面出现拐点的企业。 西南证券表示，2025年2月，国产大模型DeepSeek-R1全面开源与多领域适配，AI医疗迈入技术融合与行业重构的新阶段，DeepSeek的多模型协同能力成为 行业新范式。这种" ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that can mirror the growth of these US AI leaders, particularly those like RunDa Medical and YiMaiTong, which are positioned to leverage AI for substantial performance gains [10][12]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring domestic companies such as RunDa Medical and YiMaiTong for potential investment opportunities as they implement AI solutions [10][12]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top-performing stocks during this period included Changshan Pharmaceutical (up 23.59%) and Xiangxue Pharmaceutical (up 19.64%) [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei to implement AI solutions across over 80 hospitals, enhancing its digital healthcare offerings [12][13]. - YiMaiTong, a leading online professional physician platform in China, has seen its registered physician count grow to over 4 million, with a compound annual growth rate (CAGR) of 24.9% in paid clicks from 2018 to 2024 [17][20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and Titan Technologies, indicating a focus on firms with strong fundamentals and growth potential [5].